MX349036B - Metodos y composiciones para tratar enfermedades virales. - Google Patents

Metodos y composiciones para tratar enfermedades virales.

Info

Publication number
MX349036B
MX349036B MX2014006850A MX2014006850A MX349036B MX 349036 B MX349036 B MX 349036B MX 2014006850 A MX2014006850 A MX 2014006850A MX 2014006850 A MX2014006850 A MX 2014006850A MX 349036 B MX349036 B MX 349036B
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating viral
viral diseases
viral
Prior art date
Application number
MX2014006850A
Other languages
English (en)
Other versions
MX2014006850A (es
Inventor
Einav Shirit
Barouchbentov Rina
Neveu Gregory
Zivav Amotz
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2014006850A publication Critical patent/MX2014006850A/es
Publication of MX349036B publication Critical patent/MX349036B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
    • C12C1/00—Preparation of malt
    • C12C1/18—Preparation of malt extract or of special kinds of malt, e.g. caramel, black malt
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una sunitinib o una sal farmacéuticamente aceptable de sunitinib para usarse enla inhibición de infecciones por un Lentiviridae, HIV, coinfección de HCV/HIV, Flaviviridae diferente HCV, virus de unión de clatrina AP diferentes de Flaviviridae, o virus de unión de clatrina AP diferentes de HCV.
MX2014006850A 2011-12-06 2012-12-06 Metodos y composiciones para tratar enfermedades virales. MX349036B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161567491P 2011-12-06 2011-12-06
PCT/US2012/068167 WO2013086133A1 (en) 2011-12-06 2012-12-06 Methods and compositions for treating viral diseases

Publications (2)

Publication Number Publication Date
MX2014006850A MX2014006850A (es) 2014-11-25
MX349036B true MX349036B (es) 2017-07-07

Family

ID=48574863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006850A MX349036B (es) 2011-12-06 2012-12-06 Metodos y composiciones para tratar enfermedades virales.

Country Status (13)

Country Link
US (2) US9364484B2 (es)
EP (1) EP2787999B1 (es)
CN (1) CN104066432B (es)
AU (1) AU2012347785B2 (es)
BR (1) BR112014013649A2 (es)
CO (1) CO7230337A2 (es)
CR (1) CR20140291A (es)
MX (1) MX349036B (es)
MY (1) MY171759A (es)
PE (1) PE20142102A1 (es)
PH (1) PH12014501268B1 (es)
SG (1) SG11201402899TA (es)
WO (1) WO2013086133A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170136021A1 (en) * 2014-10-03 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating enveloped viruses
JP2023522688A (ja) * 2020-04-21 2023-05-31 レクシコン ファーマシューティカルズ インコーポレイテッド ウイルス感染症の治療に使用されるａａｋ１阻害剤

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241704B1 (en) 1901-11-22 2001-06-05 Sims Deltec, Inc. Drug pump systems and methods
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3923426A (en) 1974-08-15 1975-12-02 Alza Corp Electroosmotic pump and fluid dispenser including same
US4036228A (en) 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4016880A (en) 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4203442A (en) 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4210139A (en) 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4350155A (en) 1980-04-02 1982-09-21 Medtronic, Inc. Body implantable medical infusion system
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
AU6815894A (en) 1993-04-19 1994-11-08 Stuart A. Kauffman Random chemistry for the generation of new compounds
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5443450A (en) 1994-04-29 1995-08-22 Medtronic, Inc. Medication delivery device and method of construction
DE19509634C1 (de) 1995-03-17 1996-03-28 Fresenius Ag Implantierbare Infusionspumpe
US5643207A (en) 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
ATE281153T1 (de) 1996-02-02 2004-11-15 Alza Corp Implantierbares system mit verzögerter wirkstofffreisetzung
US5976109A (en) 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
BR9714349A (pt) 1996-10-16 2000-11-14 Icn Pharmaceuticals L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
TR199901602T2 (xx) 1996-10-18 1999-10-21 Vertex Pharmaceuticals Incorporated Serin proteazlar�n ve �zel olarak hepatit C vir�s� NS3 proteaz�n�n inhibit�rleri.
US6171276B1 (en) 1997-08-06 2001-01-09 Pharmacia & Upjohn Ab Automated delivery device and method for its operation
US6143715A (en) 1997-08-11 2000-11-07 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
PT1003775E (pt) 1997-08-11 2005-07-29 Boehringer Ingelheim Ca Ltd Peptidos inibidores da hepatite c
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6423695B1 (en) 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
AU3376699A (en) 1998-03-31 1999-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1109580A4 (en) 1998-09-04 2004-05-26 Viropharma Inc METHOD FOR TREATING OR PREVENTING VIRAL INFECTIONS AND RELATED DISEASES
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6308099B1 (en) 1998-11-13 2001-10-23 Intermedics Inc. Implantable device and programmer system which permits multiple programmers
US6198966B1 (en) 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
US6464687B1 (en) 1999-03-09 2002-10-15 Ball Semiconductor, Inc. Implantable drug delivery system
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
DE19915914C2 (de) 1999-04-08 2001-04-26 Willi Foldenauer Fütterungsvorrichtung mit Funktionsrandgestaltung
RU2223761C2 (ru) 1999-12-27 2004-02-20 Джапан Тобакко Инк. Соединения с конденсированным кольцом и их использование в качестве лекарственных средств
AU2001234837A1 (en) 2000-02-08 2001-08-20 Schering Corporation Azapeptides useful in the treatment of hepatitis c
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
DE10031274A1 (de) 2000-06-27 2002-01-10 Bosch Gmbh Robert Wischarm für Kraftfahrzeuge
US20020164600A1 (en) 2000-06-28 2002-11-07 Gordon Freeman PD-L2 molecules: novel PD-1 ligands and uses therefor
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
JP3889708B2 (ja) 2000-11-20 2007-03-07 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎トリペプチド阻害剤
MY134070A (en) 2001-01-22 2007-11-30 Isis Pharmaceuticals Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2002252183A1 (en) 2001-03-06 2002-09-19 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
WO2002089731A2 (en) 2001-05-03 2002-11-14 Stanford University Agents for treatment of hcv and methods of use
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
OA12622A (en) 2001-06-11 2006-06-12 Shire Biochem Inc Thiophene derivatives as antiviral agents for flavivirus infection.
CA2449999C (en) 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
WO2005032329A2 (en) 2003-08-22 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-hcv agents
US20070060537A1 (en) * 2005-04-28 2007-03-15 Proteologics, Inc. Methods and compositions for inhibiting viral infections
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
SI1907000T2 (sl) 2005-06-08 2020-07-31 Dana-Farber Cancer Institute Postopki in sestavki za zdravljenje persistentne HIV infekcije z inhibicijo programiranih celični smrtnih 1 (PD-1) poti
US7550400B2 (en) 2005-08-02 2009-06-23 Exxonmobil Chemical Patents Inc. Multiple layer nonwoven fabric structures
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7655419B2 (en) 2006-08-25 2010-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-HCV agents
US20110097332A1 (en) * 2007-08-06 2011-04-28 Martina Buck Composition and Method of Use for HCV Immunization
US9061010B2 (en) 2007-09-18 2015-06-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating a Flaviviridae family viral infection and compositions for treating a Flaviviridae family viral infection
CN102227237A (zh) * 2008-09-26 2011-10-26 国家健康与医学研究院 作为针对hcv感染的抗病毒治疗的靶标的宿主细胞激酶

Also Published As

Publication number Publication date
AU2012347785B2 (en) 2017-03-16
BR112014013649A2 (pt) 2020-10-27
WO2013086133A1 (en) 2013-06-13
EP2787999B1 (en) 2019-01-23
MX2014006850A (es) 2014-11-25
CR20140291A (es) 2014-10-28
MY171759A (en) 2019-10-28
PH12014501268A1 (en) 2014-09-08
PH12014501268B1 (en) 2014-09-08
EP2787999A1 (en) 2014-10-15
EP2787999A4 (en) 2015-05-13
US20170000802A1 (en) 2017-01-05
US10869873B2 (en) 2020-12-22
US20150057267A1 (en) 2015-02-26
US9364484B2 (en) 2016-06-14
PE20142102A1 (es) 2015-01-04
CN104066432A (zh) 2014-09-24
CO7230337A2 (es) 2015-03-31
AU2012347785A1 (en) 2014-06-26
CN104066432B (zh) 2017-06-13
SG11201402899TA (en) 2014-07-30

Similar Documents

Publication Publication Date Title
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
IL286427B1 (en) BCL-2 ANTI-APOPTOTIC PROTEIN FAMILY MEMBERS inhibitors for the treatment of a non-cancerous disease or a disease of the eye
WO2014031487A8 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
UA106640C2 (uk) Bcl-2-СЕЛЕКТИВНИЙ АПОПТОЗІНДУКУЮЧИЙ ЗАСІБ ДЛЯ ЛІКУВАННЯ РАКУ І ІМУННИХ ЗАХВОРЮВАНЬ
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
EP3201336A4 (en) Methods for extracting and purifying non-denatured proteins
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EP3390666A4 (en) COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES
EP3236772A4 (en) Methods of purifying recombinant proteins
EA201490265A1 (ru) Ингибиторы тирозинкиназы брутона
ZA201307442B (en) Inhibitors of viral replication. their process of preparation and their therapeutical uses
EP3512539A4 (en) METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
CA2872308A1 (en) Novel ha binding agents
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EP3209290A4 (en) Therapy for inhibition of single-stranded rna virus replication
EP3265477A4 (en) DOUBLE SIGNALING PROTEIN (DSP) FUSION PROTEINS AND METHODS OF USE THEREOF FOR THE TREATMENT OF DISEASES
EP3478658A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR POTENTIALIZING GEN SILENCING
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
EP3131556A4 (en) Methods and compositions for treatment of copd diseases
PH12014501200A1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EP3160611A4 (en) Methods and reagents for purification of proteins
EP3341112A4 (en) METHODS AND COMPOSITIONS FOR PROTEIN PURIFICATION AND REACTION OF AN ENZYME
MX2017001930A (es) Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina.

Legal Events

Date Code Title Description
FG Grant or registration